Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Assets: 2018-2025

Historic Current Assets for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $21.3 million.

  • China SXT Pharmaceuticals' Current Assets rose 18.44% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 18.44%. This contributed to the annual value of $21.3 million for FY2025, which is 49.62% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Current Assets of $21.3 million as of FY2025, which was up 49.62% from $14.2 million recorded in FY2024.
  • China SXT Pharmaceuticals' Current Assets' 5-year high stood at $23.2 million during FY2021, with a 5-year trough of $14.2 million in FY2024.
  • Moreover, its 3-year median value for Current Assets was $19.5 million (2023), whereas its average is $18.4 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Current Assets declined by 27.09% in 2024, and later surged by 49.62% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Assets (Yearly) stood at $23.2 million in 2021, then decreased by 3.36% to $22.5 million in 2022, then dropped by 13.05% to $19.5 million in 2023, then decreased by 27.09% to $14.2 million in 2024, then skyrocketed by 49.62% to $21.3 million in 2025.